Both semaglutide and tirzepatide are injectable medications that aid in managing blood sugar levels and promoting weight loss. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, while tirzepatide is a dual agonist, targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. These medications mimic incretin hormones, signaling the brain to enhance satiety and regulate metabolism. They are approved for treating type 2 diabetes and have received FDA approval for chronic weight management. However, their effectiveness is maximized when combined with lifestyle modifications, including a balanced diet and regular physical activity.